Project Grant R01AI192666
Award Date 8/5/26
Completion Date 7/31/30
Dollars Obligated $651K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22904, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $444,125 to the University of Virginia on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode immune responses during sequential rhinovirus infections. The recipient will conduct a comprehensive analysis of immune cells and anti-viral mediators in blood and nasal specimens collected during sequential homotypic and heterotypic...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $242,958 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate RNA structure probing approaches for understanding pro-inflammatory RNA helicases. The research applies chemical probing techniques—specifically co-transcriptional structure tracking (COSTSEQ) combined with DMS-MAPSEQ—to identify RNA substrates that DEAD-/DEAH-box helicases remodel and to map functional...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $713,396 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the molecular mechanisms of protective lung resident memory T cells. The project examines how lung tissue-resident memory CD8+ T cells provide broad-spectrum protection against influenza infection, including heterologous protection against variant strains. The research focuses on a...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $773,388 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode the cellular networks governing respiratory mucosal IgA immunity. The research addresses mechanisms driving robust respiratory mucosal immunity, particularly IgA responses following infection or vaccination, with the goal of informing next-generation mucosal vaccine strategies against...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $120,312 to the University of California, Berkeley on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into adenosine deaminases acting on RNA (ADARs), enzymes that edit RNA to regulate gene expression and immune responses. The research aims to identify viral and host...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.05 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Virginia on September 12, 2025, with a completion date of August 31, 2029. This research initiative investigates paired receptor signaling in natural killer (NK) cells to understand antiviral immunity and viral control mechanisms. The project employs advanced molecular...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $195,625 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing) to investigate the role of the DEAH-box RNA helicase DHX29 during class switch recombination in B cells. The research characterizes nuclear DHX29 function in antibody isotype diversification. Class switch recombination enables B cells to replace the initial immunoglobulin M isotype with distinct...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $236,660 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate IL-33-dependent and IL-33-independent pathways in allergic asthma. The project examines how IL-33 signaling drives type-2 inflammatory responses in allergic asthma and why blockade of IL-33 has produced mixed clinical trial results despite its position as an upstream therapeutic target. The...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $751,919 on June 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on transcriptional control of activation-induced deaminase function. This Project Grant (R01AI192485) funds investigation into the molecular mechanisms coordinating activation-induced deaminase (AID)-mediated deamination with RNA polymerase 2 transcription. Understanding these mechanisms is...